Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.0%

58 terminated/withdrawn out of 413 trials

Success Rate

79.9%

-6.6% vs industry average

Late-Stage Pipeline

1%

3 trials in Phase 3/4

Results Transparency

49%

112 of 230 completed trials have results

Key Signals

79 recruiting112 with results38 terminated20 withdrawn

Enrollment Performance

Analytics

N/A
136(42.8%)
Phase 2
98(30.8%)
Phase 1
66(20.8%)
Early Phase 1
15(4.7%)
Phase 3
2(0.6%)
Phase 4
1(0.3%)
318Total
N/A(136)
Phase 2(98)
Phase 1(66)
Early Phase 1(15)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (413)

Showing 20 of 413 trials
NCT07484139Phase 2Not Yet Recruiting

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

Role: lead

NCT06855654Not ApplicableRecruiting

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

Role: lead

NCT06306924Recruiting

UNC Metastatic Cancer Radiation Therapy Registry

Role: lead

NCT06727773Phase 2Recruiting

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Role: lead

NCT06348147Phase 2Suspended

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Role: lead

NCT04753086Active Not Recruiting

Patient Related Outcomes for Gynecologic Radiation Oncology

Role: lead

NCT05823740Not ApplicableCompleted

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

Role: lead

NCT07463833Not ApplicableNot Yet Recruiting

Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology

Role: lead

NCT06441487Not ApplicableActive Not Recruiting

mPATH-Cloud for Colorectal Cancer Screening

Role: lead

NCT07553520Not ApplicableWithdrawn

Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients

Role: lead

NCT07065552Early Phase 1Recruiting

Tirzepatide in Obesity-Driven Endometrial Cancer

Role: lead

NCT04564989Recruiting

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

Role: lead

NCT07545746Phase 2Not Yet Recruiting

Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya

Role: lead

NCT06702592Not ApplicableNot Yet Recruiting

Virtual Testis Cancer Lay Support and Survivorship Aim 2

Role: lead

NCT06789653Recruiting

A Novel Approach Utilizing Organ Specific Age Proteomics

Role: lead

NCT07276880Phase 2Recruiting

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Role: lead

NCT07428330Not ApplicableRecruiting

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Role: lead

NCT07304063Not ApplicableNot Yet Recruiting

Overcoming Barriers to Uptake of Cascade Screening

Role: lead

NCT06483555Phase 1Recruiting

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Role: lead

NCT04266730Phase 1Suspended

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Role: lead